ASH 2022 | Mechanism of action of the tri-specific T-cell activating construct HPN217 in R/R multiple myeloma
Al-Ola Abdallah
• 11 Dec 2022
Al-Ola Abdallah, MD, University of Kansas Medical Center, Westwood, KS, briefly describes the mechanism of action of HPN217, a tri-specific T-cell activating construct targeting three domains: B-cell maturation antigen (BCMA) on myeloma cells, CD3 for T-cell engagement, and albumin to extend the agent’s half-life. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
